Clinical trials: H1N1 Influenza
Influenza
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968539
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- Belgium
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00954798
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated)
- Where
- 6 sites in France
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus, H1N1 Subtype
Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
The purpose of this study is to compare the safety and tolerability of Zanamivir using a Rotahaler device presentation to placebo within the Rotahaler presentation and to the Diskhaler device.
- Trial name
- NAI113625 (NCT00989404)
- Testing
- Zanamivir
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
- Trial name
- NCT00976469
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated), Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
- Where
- 6 sites in Austria, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Pandemic Influenza Disease
Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10
This present study, a phase II, open label study will evaluate the immunogenicity, tolerability and safety of an adjuvanted, inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in healthy subjects…
- Trial name
- NCT00992212
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 5 sites in Italy
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
H1N1 Influenza Virus, Invasive Solid Tumors
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01031719
- Testing
- adjuvanted A(H1N1) influenza vaccine, non-adjuvanted A(H1N1) influenza vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Prophylaxis of A/H3N2v Influenza
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to <9 years, adolescents 9 to <18 years, adults 18 to <65 years and elderly 65 years and older.
- Trial name
- NCT01855945
- Testing
- Swine Influenza
- Where
- 11 sites in United States
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00952419
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine
- Where
- 20 sites in United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Seasonal Human Influenza
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
The purpose of this phase I trial is to evaluate safety and tolerability of GHB01L1 administered as single dose intranasal aerosol for vaccination against influenza A (H1N1) virus.
- Trial name
- GHBCS-01 (NCT00724997)
- Testing
- GHB01L1
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
- Trial name
- NCT00958243
- Testing
- CSL's 2009 H1N1 Influenza Vaccine (CSL425)
- Where
- 13 sites in United States
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Seqirus